Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SP 3164

Next Previous
X
Search
Drug Profile

SP 3164

Alternative Names: DRX-164; SP-3164

Latest Information Update: 27 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DeuteRx
  • Class Antineoplastics; Piperidones; Quinazolines; Small molecules
  • Mechanism of Action CRBN protein modulators; IKZF1 protein degraders; IKZF3 protein degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 22 Mar 2024 Salarius Pharma plans a phase I trial for Non-Hodgkin's lymphoma
  • 16 Jan 2024 Salarius Pharmaceuticals has patent protection for SP 3164 in USA
  • 31 Dec 2023 Salarius Pharmaceuticals has patent protection for targeted degradation of SP 3164

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top